// App-Quantinova.ai

2044 : Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Vincent Delwail

  • Shankara Paneesha

  • Simon Rule

  • Alejandro Martin Garcia-Sancho

  • Ana Marin-Niebla

  • Gilles Salles

  • Juan-Manuel Sancho

  • Vibeke Vergote

  • Vittorio Ruggero Zilioli

  • Fred Zheng

  • Douglas J DeMarini

  • Wei Jiang

  • Amitkumar Mehta

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • CHU Poitiers, Poitiers, France

  • Centre for Haematology and Stem Cell Transplantation, Heartlands Hospital, Birmingham, United Kingdom

  • Plymouth University Hospitals NHS Trust, Plymouth, United Kingdom

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • University of Lyon, Lyon, France

  • Hospital Germans Trias i Pujol, Barcelona, Spain

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Incyte Corporation, Wilmington, DE

  • UAB School of Medicine, Birmingham, AL.

Locations

  • Italy

  • France

  • United Kingdom

  • Spain

  • Belgium

  • United States

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03235544

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved